Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371547 | 1.00 | PDPK1 (0.45) | PDPK1MTORKDM1AMAOAMAOB | |
| SCHEMBL371490 | 1.00 | PDPK1 (0.45) | PDPK1MTORKDM1AMAOAMAOB | |
| SCHEMBL371546 | 1.00 | PDPK1 (0.45) | PDPK1MTORKDM1AMAOAMAOB | |
| SCHEMBL12152955 | 0.84 | BCHE (0.48) | PDPK1MTORGJB2TACR1PDE4D | |
| SCHEMBL25084017 | 0.83 | BCHE (0.47) | PDPK1MTORTACR1PDE4DSLC6A2 | |
| SCHEMBL22765220 | 0.82 | BCHE (0.49) | PDPK1MTORKDM1AGJB2TACR1 | |
| SCHEMBL22747926 | 0.82 | BCHE (0.49) | PDPK1MTORKDM1AGJB2TACR1 | |
| SCHEMBL371634 | 0.80 | BCHE (0.49) | PDPK1MTORKDM1AMAOAMAOB | |
| SCHEMBL371557 | 0.80 | BCHE (0.49) | PDPK1MTORKDM1AMAOAMAOB | |
| SCHEMBL14490126 | 0.78 | PDPK1 (0.42) | PDPK1MTORTACR1PDE4DSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093875-A1 | AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2409966-A1 | AMINOCYCLITOL COMPOUNDS, PROCEDURE FOR THE OBTAINMENT AND USES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093875-A1 | AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES | AADAT, NFATC1, PBK | PDPK1 731/4885MTOR 1209/4885KDM1A 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.